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Sodium retention and volume overload are the main determinants of poor response to renin-
angiotensin-aldosterone system (RAAS) inhibition in patients with diabetes. As volume excess
can exist without symptoms, biomarkers are needed to identify a priori which patients are vol-
ume overloaded and may experience less benefit from RAAS inhibition. N-terminal pro-brain
natriuretic peptide (NT-proBNP) is released in the setting of increased cardiac wall stress and
volume overload. We conducted a post hoc analysis among 5081 patients with type 2 diabetes
mellitus participating in the ALTITUDE trial to investigate whether NTproBNP can predict the
effects of additional therapy with aliskiren on cardio-renal endpoints. Aliskiren compared to pla-
cebo reduced the risk of the primary cardio-renal endpoint events by 20% (95% confidence
interval [CI] 16 to 61) and 2% (95% CI –42 to 30) in the two lowest NT-proBNP tertiles, and it
increased the risk by 25% (95% CI –4 to 96) in the highest NT-proBNP tertile (P value for
trend = 0.009). Similar trends were observed for the cardiovascular and end-stage renal disease
endpoints. Effects of aliskiren compared to placebo on safety outcomes (hyperkalaemia and hos-
pitalization for acute kidney injury) were independent of NT-proBNP. In conclusion, baseline
NT-proBNP may be used as a marker to predict the response to aliskiren with regard to cardio-
renal outcomes when added to standard therapy with RAAS inhibition.
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1 | INTRODUCTION
The antihypertensive and anti-albuminuric response to renin-angio-
tensin-aldosterone system (RAAS) therapy varies considerably
among people with type 2 diabetes.1,2 People with type 2 diabetes
are susceptible to retaining sodium and fluid as a result of disturbed
insulin homeostasis.3 Previous studies have shown that sodium
retention and subsequent volume overload are the main determi-
nants of poor response to RAAS therapy.4,5 Accordingly, volume
restriction by means of co-diuretic treatment or a low sodium diet
enhances the blood pressure-lowering and albuminuria-reducing
effects of RAAS inhibition.6 Diuretic treatment is therefore recom-
mended, although not always implemented in clinical practice. As
volume excess can exist without symptoms, it is difficult to identify
Received: 6 June 2018 Revised: 29 June 2018 Accepted: 5 July 2018
DOI: 10.1111/dom.13465
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
© 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Diabetes Obes Metab. 2018;20:2899–2904. wileyonlinelibrary.com/journal/dom 2899
a priori which patients are volume overloaded and will have a less
beneficial response to RAAS inhibition; therefore, biomarkers that
represent volume status and response to RAAS inhibition are
desired.
N-terminal pro-brain natriuretic peptide (NT-proBNP) is secreted
from the ventricular myocardium in response to increased myocyte
stress and volume overload.7 This suggests that high levels of NT-
proBNP may be a marker of excess volume overload in patients with-
out overt heart failure and may be an indicator of response to RAAS
intervention.
To test this hypothesis, we performed a post hoc analysis of the
ALTITUDE trial in which patients with type 2 diabetes with increased
cardiovascular or renal risk were randomly assigned to aliskiren or pla-
cebo treatment on top of treatment with angiotensin-converting
enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). The
aim of the present study was to determine whether NT-proBNP pre-
dicts the response to aliskiren on cardio-renal endpoints.
2 | MATERIALS AND METHODS
2.1 | Participants and study design
The ALTITUDE trial was a randomized, double-blind, placebo-
controlled trial conducted at 854 centres in 36 countries. The study
design and principal findings have been published previously.8 In
short, 8561 people with type 2 diabetes mellitus at high risk of cardio-
vascular and renal events were assigned to either aliskiren 300 mg/d
or matched placebo in addition to antihypertensive therapy consisting
of an individually titrated optimal recommended dose of ACE inhibitor
or ARB, but not both. Randomized participants were followed for a
median of 32.9 months for occurrence of cardiovascular and renal
events. Inclusion criteria were: persistent macroalbuminuria (urinary
albumin:creatinine ratio [UACR] ≥200 mg/g), an estimated glomerular
filtration rate (eGFR) of ≥30 to ≤60 mL/min/1.73 m2 and persistent
microalbuminuria (UACR ≥20 mg/g to ≤200 mg/g), or a history of car-
diovascular disease (including heart failure New York Heart Associa-
tion class I/II) and an eGFR of ≥30 and < 60 mL/min/1.73 m2. All
participants signed informed consent before enrolment, and the study
was approved by the local institutional review board of each partici-
pating centre.
2.2 | Measurements and outcomes
At each visit, participants submitted three consecutive first morning
void samples. Urinary albumin (mg/L) and creatinine (g/L), and thereby
UACR, were measured in each first morning void sample by immuno-
turbidimetry. The geometric mean of UACR was calculated from the
three first morning void samples and used for analysis. Serum creati-
nine concentration was measured by Jaffe reaction (Roche Diagnos-
tics, Risch-Rotkreuz, Switzerland). Blood pressure was measured using
an automated validated device, while the patient was in a sitting posi-
tion. The mean of three blood pressure measurements with 1- to
2-minute intervals was used for analysis. eGFR was calculated with
the Modification of Diet in Renal Disease formula.9 NT-proBNP was
measured in plasma at baseline. All laboratory analyses, including first
morning void urine analysis, were performed at central laboratories in
Europe or the United States.
The primary cardio-renal endpoint was defined as a composite of
cardiac arrest with resuscitation, non-fatal myocardial infarction, non-
fatal stroke, unplanned hospitalization for heart failure, cardiovascular
death, end-stage renal disease (defined as the need for chronic dialy-
sis, renal transplantation or a serum creatinine concentration > 530
μmol/L [6.0 mg/dL] sustained for at least 1 month), doubling of serum
creatinine, or death attributable to kidney failure, defined as the need
for renal-replacement therapy with no dialysis or transplantation avail-
able or initiated. Safety outcomes included acute kidney injury and
hyperkalaemia. All endpoints were adjudicated by a central endpoint
committee using rigorous definitions.
2.3 | Statistical analysis
The effect of aliskiren compared to placebo on cardio-renal and safety
outcomes in tertiles of baseline NT-proBNP as well as for continuous
measures of NT-proBNP was estimated from unadjusted Cox propor-
tional hazard regression models. For participants who experienced >1
primary event, survival time to the first renal or cardiovascular event
was used in each analysis. Participants who did not have an endpoint
of interest during the study were censored at the study cut-off date.
Test for trends in treatment effects across NT-proBNP tertiles as cat-
egorical and continuous variables were conducted by adding interac-
tion terms (NT-proBNP * treatment assignment) to the relevant Cox
models. In an additional analysis, the Cox model was adjusted for age,
gender, UACR, eGFR, systolic blood pressure (SBP), diastolic blood
pressure, glycated haemoglobin, body mass index, LDL cholesterol,
HDL cholesterol, triglycerides, history of cardiovascular disease
(yes/no), haemoglobin, potassium, use of diuretics, smoking status
(yes/no), and alcohol consumption (yes/no) to assess whether the
interaction between baseline NT-proBNP and treatment assignment
persisted after accounting for differences in these variables across
NT-proBNP tertiles. These covariates were chosen in accordance with
previous analyses in this population. To further delineate the relation-
ship between baseline levels of NT-proBNP and the cardio-renal end-
points, a subpopulation treatment effect pattern plot (STEPP) was
used to explore patterns of treatment effect for varying levels of base-
line NT-proBNP. STEPP enables the calculation of drug estimates
along a continuous scale with overlapping participant subgroups.10,11
An analysis of covariance (ANCOVA) model was used to assess the
treatment effect on albuminuria and blood pressure at month 6. Tests
for trends in treatment effects were assessed by adding an interaction
term to the ANCOVA model.
For continuous variables that are not normally distributed, such
as NT-proBNP and UACR, a natural log transformation was applied
before analysis to fulfil assumptions for regression analyses. Differ-
ences in baseline characteristics across NT-proBNP tertiles were
tested using analysis of variance, with Bonferroni adjustments for
multiple comparisons for continuous variables. χ2 tests were used to
test for differences in categorical variables.
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Two-sided P values <0.05 were taken to indicate statistical signifi-
cance. Data were analysed with SAS version 9.3 (SAS Institute, Cary,
North Carolina).
3 | RESULTS
Of the 8561 participants enrolled in the ALTITUDE trial, 5081 (59.5%)
had NT-proBNP measurements available and did not have a history of
congestive heart failure at baseline. These were included in the analysis.
In comparing the characteristics of the overall ALTITUDE population
with those in whom NT-proBNP was measured, no relevant differences
were observed (Table S1). The baseline characteristics stratified by ter-
tile of baseline NT-proBNP are shown in Table 1. Median NT-proBNP
levels in increasing tertiles of NT-proBNP were 50, 157 and 534 ng/L,
respectively. Participants in the lower NT-proBNP tertile were younger,
had lower SBP, a higher eGFR, were less likely to have a cardiovascular
disease history, and less likely to use β-blockers or diuretics (Table 1).
3.1 | Baseline NT-pro BNP predicts effects of
aliskiren
The effect of aliskiren compared with placebo on albuminuria and SBP
was modified by baseline NT-proBNP level (P for interaction albumin-
uria = 0.004 and P for interaction systolic SBP = 0.009). In the aliski-
ren group, compared with the placebo group, there was a significant
reduction in UACR and SBP of 22.2% (95% CI –29.0 to −14.8) and
3.2 mm Hg (95% CI –5.0 to −1.4), respectively, in the lowest NT-
proBNP tertile, whereas aliskiren had no effect on these surrogates in
the upper NT-proBNP tertile (Figure S1).
The effects of aliskiren on cardio-renal endpoints were also modi-
fied by baseline NT-proBNP level (P for interaction = 0.009). In the
upper NT-proBNP tertile, aliskiren compared with placebo increased
the risk of the cardio-renal endpoint (hazard ratio [HR] 1.25 [95% CI
1.04–1.51]), whereas the HRs associated with aliskiren treatment in
the middle and lower tertile were 0.96 (95% CI 0.76–1.26) and 0.80
TABLE 1 Baseline characteristics stratified by tertiles of baseline N-terminal pro-brain natriuretic peptide
Tertile 1 Tertile 2 Tertile 3
Placebo Aliskiren Placebo Aliskiren Placebo Aliskiren
Number of patients 856 846 860 828 832 859
NT-proBNP, ng/L 50 (2.5, 95) 50 (2.5, 95) 157 (95, 266) 158 (95, 273) 524 (266, 40 500) 544 (266, 40 500)
Agea, y 59.7 (9.7) 59.9 (9.4) 64.7 (9.2) 65.1 (9.0) 67.5 (9.1) 67.2 (9.1)
Gendera, n (%)
Men 623 (72.8) 610 (72.1) 566 (65.8) 545 (65.8) 574 (69.0) 586 (68.2)
Women 233 (27.2) 236 (27.9) 294 (34.2) 283 (34.2) 258 (31.0) 273 (31.8)
Racea, n (%)
White 364 (43.0) 379 (45.2) 469 (54.2) 436 (52.5) 498 (59.5) 518 (60.0)
Black 31 (3.7) 22 (2.6) 19 (2.2) 16 (1.9) 17 (2.0) 7 (0.8)
Hispanic 409 (48.3) 382 (45.5) 333 (38.5) 327 (39.4) 254 (30.3) 280 (32.4)
Other 42 (4.9) 56 (6.6) 44 (5.1) 52 (6.2) 68 (8.1) 58 (6.7)
SBPa, mm Hg 133.3 (15.2) 133.0 (14.7) 137.8 (16.2) 138.1 (15.2) 141.6 (17.0) 140.9 (17.0)
DBPa, mm Hg 76.0 (8.8) 76.3 (8.7) 73.8 (9.5) 73.7 (9.2) 73.5 (10.6) 73.3 (10.7)
Body mass index, kg/m2 29.5 (5.9) 29.6 (5.6) 29.5 (5.7) 29.7 (5.9) 29.2 (5.7) 29.2 (5.8)
Haemoglobina, g/L 137 (16) 136 (16) 130 (17) 131 (17) 127 (18) 127 (18)
HbA1ca, mmol/mol 62 (13) 63 (13) 61 (13) 61 (12) 60 (12) 60 (12)
HDL cholesterola, (mmol/L) 1.18 (0.30) 1.17 (0.31) 1.21 (0.35) 1.21 (0.32) 1.22 (0.34) 1.20 (0.35)
LDL cholesterola, (mmol/L) 2.64 (0.94) 2.60 (0.92) 2.53 (1.00) 2.58 (0.95) 2.50 (0.96) 2.53 (1.00)
Triglyceridesa, (mmol/L) 5.68 (4.48) 5.69 (4.99) 4.82 (3.35) 4.75 (2.86) 4.28 (2.55) 4.55 (3.39)
eGFRa, b, mL/min/1.73 m2 67.8 (28.2) 66.4 (27.0) 56.2 (20.0) 56.1 (20.3) 50.4 (17.3) 52.0 (17.8)
UACRa, mg/g 352 (149, 841) 337 (132, 766) 290 (62, 1006) 314 (60, 891) 326 (55, 1253) 324 (64, 1277)
History of CV diseasea, n (%) 175 (20.4) 171 (20.2) 301 (35.0) 280 (33.8) 416 (50.0) 405 (47.1)
Diabetic retinopathy, n (%) 315 (37.2) 304 (36.2) 314 (36.3) 336 (40.4) 345 (41.2) 342 (39.6)
Concomitant medication, n (%)
β-blockersa 268 (31.3) 263 (31.1) 407 (47.3) 405 (48.9) 504 (60.6) 524 (61.0)
Diureticsa 430 (50.2) 431 (50.9) 512 (59.5) 493 (59.5) 560 (67.3) 556 (64.7)
Insulina 485 (56.7) 481 (56.9) 500 (58.1) 496 (59.9) 481 (57.8) 516 (60.1)
Sulphonylureas 265 (31.3) 255 (30.4) 276 (31.9) 255 (30.7) 273 (32.6) 267 (30.9)
Biguanidesa 426 (50.4) 424 (50.5) 363 (42.0) 362 (41.9) 347 (41.5) 362 (41.9)
Abbreviations: CV, cardiovascular; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; IQR, interquar-
tile range; NT-proBNP, N-terminal pro-brain natriuretic peptide; SBP, systolic blood pressure; UACR, urinary albumin:creatinine ratio. Within each tertile,
values are stratified for treatment with aliskiren or placebo. Numeric variables are presented as mean (SD) if normally distributed and skewed data were
presented as median (IQR). NT-proBNP is presented as median (range). Categorical variables are presented as frequency (%).
a Statistically significant between tertiles of NT-proBNP.
b Calculated with the Modification of Diet in Renal Disease study equation.
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FIGURE 1 Effect of aliskiren vs placebo on cardiovascular (CV) and renal endpoints, and safety outcomes (acute kidney injury, hospitalization for
acute kidney injury and hyperkalaemia) according to baseline N-terminal pro-brain natriuretic peptide tertile. Solid boxes represent estimates of
treatment effects. The centre of the boxes is placed on the estimate of the treatment effect, the horizontal line represents the width of the 95%
confidence interval (CI). The primary cardio-renal endpoint was defined as a composite of cardiac arrest with resuscitation, non-fatal myocardial
infarction, non-fatal stroke, unplanned hospitalization for heart failure (HF), CV death, end-stage renal disease (defined as the need for chronic
dialysis, renal transplantation or a serum creatinine concentration > 530 μmol/L [6.0 mg/dL] sustained for at least 1 month), doubling of serum
creatinine, or death attributable to kidney failure, defined as the need for renal-replacement therapy with no dialysis or transplantation available
or initiated. The secondary CV endpoint was defined as a composite of cardiac arrest with resuscitation, non-fatal myocardial infarction, non-fatal
stroke, unplanned hospitalization for HF and CV death
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(95% CI 0.58–1.10), respectively (Figure 1). A statistically significant
trend across NT-proBNP tertiles was also observed for the cardiovas-
cular endpoint, myocardial infarction and stroke. A similar trend was
observed for end-stage renal disease and hospitalization for heart fail-
ure, although these trends did not reach statistical significance, possi-
bly because of the relatively small number of events. The interaction
between aliskiren assignment and NT-proBNP levels persisted
(P = 0.005 for the composite cardio-renal endpoint) in a multivariable
adjusted model. Additionally, there was no difference in interaction
between NT-proBNP and aliskiren between participants with and
without diuretic use at baseline (P = 0.48). The STEPP analyses, in
which NT-proBNP was defined as a continuous instead of a categori-
cal variable, provided results similar to the main analysis and showed
that aliskiren tended to increase the risk of cardiorenal events at
higher NT-proBNP levels (Figure S2).
3.2 | Effect of aliskiren vs placebo on safety
outcomes according to baseline NT-proBNP levels
The HRs for adverse event rates in the aliskiren group vs placebo
according to NT-proBNP tertile are shown in Figure 1. The adminis-
tration of aliskiren resulted in similar relative effects on hyperkalae-
mia, acute kidney injury or hospitalization for acute kidney injury,
irrespective of baseline NT-proBNP levels.
4 | DISCUSSION
The present study shows that the relative risks for cardiovascular and
renal events achieved with the direct renin inhibitor aliskiren as
adjunct to RAAS blockade are modified by baseline NT-proBNP levels.
At higher NT-proBNP levels, aliskiren compared to placebo increased
the risk of the cardio-renal endpoint, while in the lower NT-proBNP
tertile, treatment with aliskiren tended to reduce cardio-renal risk.
These results suggest that NT-proBNP, a marker of vascular wall
stress and fluid overload, can possibly be used to identify patients
more likely to respond to dual RAAS inhibition with aliskiren.
Volume overload is frequently observed in patients with type
2 diabetes at high cardio-renal risk.12,13 Extracellular volume restric-
tion, by means of moderating dietary sodium intake or concomitant
diuretic treatment has been shown to improve the albuminuria-
reducing and blood pressure-lowering response to RAAS blockade as
well as the efficacy of RAAS blockade to decrease cardio-renal
risk.5,14,15 The present study shows that NT-proBNP can help to iden-
tify individuals who may not respond to dual RAAS inhibition with
aliskiren and who may benefit from diuretic treatment or dietary
sodium-lowering. Indeed, it has been shown that hydrochlorothiazide
or a low sodium diet is particularly effective in reducing albuminuria
and lowering blood pressure in patients with NT-proBNP levels
>125 pg/mL who were already receiving a maximum dose of losar-
tan.16 Whether diuretic treatment or a low sodium diet as adjunct to
RAAS blockade will prevent cardio-renal endpoints in patients with
high NT-proBNP requires further study.
The primary results of the ALTITUDE trial showed that aliskiren
did not confer renal or cardiovascular protection in patients with type
2 diabetes at high risk. We previously showed that patients with
a > 30% reduction in albuminuria during the first 6 months of the
ALTITUDE trial had a substantially lower cardio-renal risk compared
to patients with a modest increase in albuminuria.17 We now extend
these findings and demonstrate that baseline NT-proBNP enables the
selection of subgroups of patients who will or will not benefit from
aliskiren. We also showed that low and high NT-proBNP levels were
independently associated with presence or absence of a reduction in
SBP and UACR, while adverse event rates, including hyperkalaemia
and acute kidney injury, were similar across NT-proBNP tertiles.
Moreover, these results support our previous finding that patients
with a lack of reduction in albuminuria were probably volume over-
loaded and therefore did not respond to aliskiren.
How do the results of our study relate to the current literature? A
previous post hoc analysis of the I-PRESERVE trial in patients with heart
failure showed that, although NT-proBNP independently predicted all-
cause mortality and cardiovascular hospitalizations, the response to
ARB therapy was attenuated with higher NT-proBNP levels.18 Addition-
ally, the efficacy of statins in patients with elevated cardiovascular risk
also appears to be higher in patients with lower NT-proBNP levels,
although the mechanisms by which statin treatment would be more
beneficial in patients with low NT-proBNP are incompletely under-
stood.19,20 The present study extends these previous findings to a
broad population of patients with type 2 diabetes with or without car-
diovascular disease and varying levels of kidney function and
albuminuria.
The main limitation of this post hoc analysis of the data from
ALTITUDE is that sodium intake and diuretic use were not standard-
ized. Indeed during the trial, participants were advised to start diuretic
treatment; however, this limitation may have led to an underestima-
tion of the reported interaction between the aliskiren treatment
effects and NT-proBNP levels. Secondly, significant differences in
baseline characteristics were observed across NT-proBNP tertiles. It is
therefore possible that participants in the highest NT-proBNP tertile
were sicker and therefore responded poorly to aliskiren, independent
of the actual NT-proBNP level; however, in multivariable Cox regres-
sion analyses the interaction between aliskiren treatment and NT-
proBNP persisted, suggesting that the interaction was independent of
other patient and disease characteristics. Nevertheless, we cannot
exclude residual confounding, and a prospectively designed clinical
trial is required to prove this hypothesis.
In conclusion, NT-proBNP, a marker reflecting volume overload,
may predict the effect of the response to aliskiren on surrogate and
clinical outcomes when added to conventional therapy with RAAS
blockade in patients with type 2 diabetes at high renal or
cardiovascular risk.
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